Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Shanghai Taiwei Pharmaceutical Corp. Ltd. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 2 distinct examiners and distinct art units. Derek James Rhoades is the busiest examiner for the company, managing 1 of the pending office actions. The current prosecution for Shanghai Taiwei Pharmaceutical Corp. Ltd. is split between these distinct examiners.
The company's 2 pending office actions are distributed across distinct examiners, each of whom is responsible for a single action. This prosecution takes place within 2 distinct art units, indicating a diverse technical review process within the Biotechnology & Pharmaceuticals sector. Derek James Rhoades is one of the examiners currently reviewing the company's applications. By working with distinct examiners, Shanghai Taiwei Pharmaceutical Corp. Ltd. can benefit from different examination styles and ensure that its portfolio is not overly dependent on a single examiner's interpretation.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RHOADES, DEREK JAMES | 1 | 72.3% | +16.5% |
| CARR, DEBORAH D | 1 | 81.8% | +2.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17830423 | SELF-AGGREGATING HYDROUS PHOSPHOLIPID AND PREPARATION METHOD THEREOF | CARR, DEBORAH D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18557294 | PHOSPHOLIPID PROCESSING AID AND APPLICATION THEREOF | RHOADES, DEREK JAMES | — |
| Art Unit | Apps |
|---|---|
| 1692 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18557294 | PHOSPHOLIPID PROCESSING AID AND APPLICATION THEREOF | RHOADES, DEREK JAMES | 1692 | §112 | Non-Final OA | — | Pending | Mar 22, 2024 |
| 17830423 | SELF-AGGREGATING HYDROUS PHOSPHOLIPID AND PREPARATION METHOD THEREOF | CARR, DEBORAH D | 1691 | §103 | Non-Final OA | — | Pending | Jun 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Taiwei Pharmaceutical Corp. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Derek James Rhoades has the most, with 1 of Shanghai Taiwei Pharmaceutical Corp. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
